Product Information
SPIRIVA RESPIMAT 1.25 MCG INH is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $126.0756 per GM under NDC 00597016061. Its NADAC has been published 550 times since Mar 23, 2016.
Strength
1.562 ug/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597016061
Classification
Brand
Dosage Form
SPRAY, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
TIOTROPIUM BROMIDE ANHYDROUSApproval Type
New Drug (NDA)
FDA Application
NDA207070On Market Since
9/15/2015
Pharmacological Classes
Price Statistics
The NADAC for SPIRIVA RESPIMAT 1.25 MCG INH has been published 550 times since Mar 23, 2016, and over the history we have for it it has risen 69.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $126.0756 per GM |
|---|---|
| All-time high | $126.3020 (Sep 11, 2024) |
| All-time low | $74.1950 (Mar 23, 2016) |
| 52-week high | $126.1645 |
| 52-week low | $126.0739 |
| Median price | $114.5362 |
| Average price | $110.4171 |
| Largest weekly change | +8.0% (Jan 10, 2018) |
| Weeks tracked | 550 |
| Tracking since | Mar 23, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tiotropium bromide inhalation spray market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tiotropium bromide inhalation spray market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SPIRIVA RESPIMAT 1.25 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for SPIRIVA RESPIMAT 1.25 MCG INH, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $126.0756 per GM (NDC 00597016061), effective Sep 30, 2026.
How has the price of SPIRIVA RESPIMAT 1.25 MCG INH changed over time?
Over the history we have for it, the NADAC for SPIRIVA RESPIMAT 1.25 MCG INH has risen 69.9%. It has been tracked across 550 weekly CMS publications since Mar 23, 2016.
What are the highest and lowest recorded NADAC prices for SPIRIVA RESPIMAT 1.25 MCG INH?
Since Mar 23, 2016, the NADAC for SPIRIVA RESPIMAT 1.25 MCG INH has ranged from a low of $74.1950 (Mar 23, 2016) to a high of $126.3020 (Sep 11, 2024), with a median of $114.5362 per GM.
Are there cheaper alternatives to SPIRIVA RESPIMAT 1.25 MCG INH?
No other NADAC-published product currently shares the active ingredient and strength of SPIRIVA RESPIMAT 1.25 MCG INH in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SPIRIVA RESPIMAT 1.25 MCG INH?
SPIRIVA RESPIMAT 1.25 MCG INH (NDC 00597016061) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.